Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 276 | 6p21.32 | PSMB8 | proteasome 20S subunit beta 8 | |
| Mouse | - | 276 | 17 17.98 cM | Psmb8 | proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7) | |
| Rat | - | 276 | 20p12 | Psmb8 | proteasome 20S subunit beta 8 | |
| Previous and Unofficial Names |
| large multifunctional protease 7 | Lmp7 | low molecular mass protein 7 | macropain subunit C13 | multicatalytic endopeptidase complex subunit C13 | proteasome component C13 | proteasome subunit beta-5i | proteasome subunit MC13 | Ring10 | proteasome (prosome, macropain) subunit, beta type, 8 | proteasome (prosome | proteasome subunit beta 8 |
| Database Links |
|
| Specialist databases | |
| MEROPS | T01.015 (Hs) |
| Other databases | |
| Alphafold | P28062 (Hs), P28063 (Mm), P28064 (Rn) |
| BRENDA | 3.4.25.1 |
| CATH/Gene3D | 3.60.20.10 |
| ChEMBL Target | CHEMBL5620 (Hs), CHEMBL1944492 (Mm) |
| DrugBank Target | P28062 (Hs) |
| Ensembl Gene | ENSG00000204264 (Hs), ENSMUSG00000024338 (Mm), ENSRNOG00000000456 (Rn) |
| Entrez Gene | 5696 (Hs), 16913 (Mm), 24968 (Rn) |
| Human Protein Atlas | ENSG00000204264 (Hs) |
| KEGG Enzyme | 3.4.25.1 |
| KEGG Gene | hsa:5696 (Hs), mmu:16913 (Mm), rno:24968 (Rn) |
| OMIM | 177046 (Hs) |
| Orphanet | ORPHA258610 (Hs) |
| Pharos | P28062 (Hs) |
| RefSeq Nucleotide | NM_004159 (Hs), NM_148919 (Hs), NM_010724 (Mm), NM_080767 (Rn) |
| RefSeq Protein | NP_004150 (Hs), NP_683720 (Hs), NP_034854 (Mm), NP_542945 (Rn) |
| UniProtKB | P28062 (Hs), P28063 (Mm), P28064 (Rn) |
| Wikipedia | PSMB8 (Hs) |
| Enzyme Reaction |
||||
|
||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| View species-specific inhibitor tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| PSMB8 is a component of the immunoproteasome [5]. It is a IFN-γ-inducible gene [1], expressed by immune and non-immune cell types [7]. Genetic mutations in PSMB8 [2-3] have been identified in patients with the autoinflammatory disorder, CANDLE syndrome [9]. |
| Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
1. Basler M, Kirk CJ, Groettrup M. (2013) The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol, 25 (1): 74-80. [PMID:23219269]
2. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, Almeida de Jesus A et al.. (2015) Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest, 125 (11): 4196-211. [PMID:26524591]
3. Cavalcante MP, Brunelli JB, Miranda CC, Novak GV, Malle L, Aikawa NE, Jesus AA, Silva CA. (2016) CANDLE syndrome: chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature-a rare case with a novel mutation. Eur J Pediatr, 175 (5): 735-40. [PMID:26567544]
4. Fan H, Angelo NG, Warren JD, Nathan CF, Lin G. (2014) Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. ACS Med Chem Lett, 5 (4): 405-10. [PMID:24900849]
5. Ferrington DA, Gregerson DS. (2012) Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci, 109: 75-112. [PMID:22727420]
6. Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, Moebius DC, Kirk C, McMinn DL. (2018) Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem, 61 (24): 11127-11143. [PMID:30380863]
7. Keller IE, Vosyka O, Takenaka S, Kloß A, Dahlmann B, Willems LI, Verdoes M, Overkleeft HS, Marcos E, Adnot S et al.. (2015) Regulation of immunoproteasome function in the lung. Sci Rep, 5: 10230. [PMID:25989070]
8. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J et al.. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med, 15 (7): 781-7. [PMID:19525961]
9. Torrelo A, Colmenero I, Requena L, Paller AS, Ramot Y, Richard Lee CC, Vera A, Zlotogorski A, Goldbach-Mansky R, Kutzner H. (2015) Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome. Am J Dermatopathol, 37 (7): 517-22. [PMID:26091509]
T1: Proteasome: proteasome 20S subunit beta 8. Last modified on 12/09/2019. Accessed on 07/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2408.
target has curated data in GtoImmuPdb
